Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 524

Similar articles for PubMed (Select 11589865)

1.

Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.

CHAMPS Study Group.

Am J Ophthalmol. 2001 Oct;132(4):463-71.

PMID:
11589865
2.

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW.

N Engl J Med. 2000 Sep 28;343(13):898-904.

3.

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, Selhorst JB, Rose JW, Cooper JA, Rice G, Murray TJ, Sandrock AW.

Ann Neurol. 2002 Apr;51(4):481-90.

PMID:
11921054
4.

Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis.

Siddiqui MA, Wellington K.

CNS Drugs. 2005;19(1):55-61; discussion 63-4. Review.

PMID:
15651905
5.

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, Hartung H, Seeldrayers P, Sørensen PS, Rovaris M, Martinelli V, Hommes OR; Early Treatment of Multiple Sclerosis Study Group.

Lancet. 2001 May 19;357(9268):1576-82.

PMID:
11377645
7.

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, Millefiorini E, Galgani S, Buttinelli C, Perciaccante G, Piazza G, Bozzao L, Fieschi C.

J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):251-8.

8.

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial.

Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, Comi G.

Lancet. 2004 Oct 23-29;364(9444):1489-96.

PMID:
15500893
9.

Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.

Pakdaman H, Sahraian MA, Fallah A, Pakdaman R, Ghareghozli K, Ghafarpour M, Rahimian E, Shirani A.

Acta Neurol Scand. 2007 Jun;115(6):429-31.

PMID:
17511854
10.

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al.

Ann Neurol. 1996 Mar;39(3):285-94. Erratum in: Ann Neurol 1996 Sep;40(3):480.

PMID:
8602746
11.

Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.

Minagara A, Murray TJ; PROOF Study Investigators.

Curr Med Res Opin. 2008 Apr;24(4):1049-55. doi: 10.1185/030079908X280545 . Epub 2008 Feb 29.

PMID:
18315940
12.

Early relapse in multiple sclerosis-associated optic neuritis following the use of interferon beta-1a in Chinese patients.

Wang AG, Lin YC, Wang SJ, Tsai CP, Yen MY.

Jpn J Ophthalmol. 2006 Nov-Dec;50(6):537-42. Epub 2006 Dec 18.

PMID:
17180529
13.

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.

Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O'Connor PW, Simon JH; Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance Investigators.

Arch Neurol. 2012 Feb;69(2):183-90. doi: 10.1001/archneurol.2011.1426. Epub 2011 Oct 10.

PMID:
21987393
14.

Acute demyelinating optic neuritis.

Foroozan R, Buono LM, Savino PJ, Sergott RC.

Curr Opin Ophthalmol. 2002 Dec;13(6):375-80. Review.

PMID:
12441840
15.

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group.

Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH.

N Engl J Med. 1993 Dec 9;329(24):1764-9.

16.
17.

MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.

Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C.

Mult Scler. 2002 Apr;8(2):119-23.

PMID:
11990868
18.
19.

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Whitham RH, et al.

Ann Neurol. 1998 Jan;43(1):79-87.

PMID:
9450771
20.

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M; Independent Comparison of Interferon (INCOMIN) Trial Study Group.

Lancet. 2002 Apr 27;359(9316):1453-60.

PMID:
11988242
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk